Xortx Therapeutics Stock Profit Margin
| XRTX Stock | 1.75 0.01 0.57% |
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
| Last Reported | Projected for Next Year |
XORTX | Profit Margin |
XORTX Therapeutics Company Profit Margin Analysis
XORTX Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
XORTX Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Profit Margin. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, XORTX Therapeutics has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all Canada stocks is 100.0% lower than that of the firm.
XORTX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 8.0M | 10.1M | 11.3M | 134.3M | 5.7M | 5.5M | |
| Enterprise Value | 7.8M | 10.1M | 11.2M | 123.9M | 2.3M | 2.2M |
XORTX Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 2.5 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 8.82 K | ||||
| Price To Book | 1.88 X | ||||
| EBITDA | (3.3 M) | ||||
| Net Income | (2.16 M) | ||||
| Total Debt | 825.94 K | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | 0.17 X | ||||
| Target Price | 81.0 | ||||
| Beta | -0.21 | ||||
| Market Capitalization | 5.64 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (17.85 M) | ||||
| Working Capital | 3.77 M | ||||
| Net Asset | 5.47 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.